Effect of fingolimod on brain and cognition
What it found
No result yet.
What was tested
Treatment tested
Compared with
- Interferon beta-1b
Interferon alpha/beta receptor agonist
- Glatiramer acetate
Unknown
What it measured
Main measures
- Improved neuropsychological test performance
Other measures (1)
NA
Who could take part
Relapsing MS
Inclusion: - Subjects should be between 18 and 65 years of age Exclusion: - Presence or history of psychiatric or neurological disease (for patients: neurological disease other than MS)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To investigate whether the disproportionally strong clinical effects of fingolimod in RRMS can be explained by enhanced functional brain adaptation and whether enhanced functional adaptation is sustained over time
Papers
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Oct 2014
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error